Related Experiment Video

Updated: Jul 11, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Effects of cardiac resynchronization therapy on insulin-like growth factor-1 in patients with advanced heart failure

Giulio Molon1, Edoardo Adamo, Gaetano M De Ferrari

  • 1Department of Cardiology, Sacro Cuore Hospital, don Calabria, Via don A. Sempreboni, Negrar, Verona, Italy. giulio.molon@sacrocuore.it

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|October 2, 2007
PubMed

Insights

Cardiac resynchronization therapy (CRT) significantly increases insulin-like growth factor-1 (IGF-1) levels in advanced heart failure patients. This rise correlates with improved quality of life, suggesting IGF-1 may mediate early symptom relief.

Area of Science:

  • Cardiology
  • Endocrinology
  • Heart Failure Research

Background:

  • Cardiac resynchronization therapy (CRT) is known to improve heart failure symptoms through neurohormonal changes.
  • The specific impact of CRT on insulin-like growth factor-1 (IGF-1) levels remains uninvestigated.

Purpose of the Study:

  • To evaluate the effect of CRT on plasma IGF-1 levels in patients with advanced heart failure.
  • To explore the correlation between changes in IGF-1, quality of life, and left ventricular (LV) function post-CRT.

Main Methods:

  • A cohort of 18 patients with advanced heart failure (NYHA class III/IV, LVEF ≤40%, QRS ≥130ms or dyssynchrony) received CRT.
  • Measurements of IGF-1, quality of life, and LV ejection fraction (LVEF) were taken at baseline and after 3 months of CRT.

Main Results:

  • After 3 months of CRT, significant improvements were observed in LVEF (29% to 33%) and quality of life.
  • Plasma IGF-1 levels increased significantly from 137 ng/ml to 175 ng/ml (P=0.01353).
  • The improvement in quality of life showed a significant correlation with the increase in IGF-1 levels (P=0.02), but not with LVEF changes.

Conclusions:

  • CRT significantly elevates plasma IGF-1 levels within 3 months in patients with advanced heart failure.
  • The increase in IGF-1 is associated with enhanced quality of life, independent of LVEF improvements.
  • IGF-1 may act as an early mediator of symptomatic benefits following CRT.
Abstract

More Related Videos

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...